Aptevo Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Aptevo Therapeutics Inc (APVO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Aptevo Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 13M vs 459,039M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-497.0% annualized vs trailing 12 months), vs accelerating (+3.4%) for its tracked peer group.
- Scale: Aptevo Therapeutics Inc ranks #459 of 543 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.36M compares with $1.00M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Aptevo Therapeutics Inc vs. its Competitors, Q2 2026
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Aptevo Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Aptevo Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Aptevo Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Aptevo Therapeutics Inc's competitor groups requires a Commercial License.
Aptevo Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Aptevo Therapeutics Inc | - | - | - | No |
| Competitors combined (103) | ||||
| High-Confidence Competitors (15) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
APVO Stock Performance relative to its Competitors
APVO Stock Performance relative to High-Confidence Competitors
APVO Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Erasca Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Centessa Pharmaceuticals Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Aptevo Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Aptevo Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Aptevo Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Aptevo Therapeutics Inc |
0.79 | 12.99 |
 Eli Lilly And Company |
1,278,223.12 | 86,462.00 |
 Johnson and Johnson |
694,227.07 | 99,335.00 |
 Merck and Co Inc |
362,966.50 | 66,569.00 |
 Novartis Ag |
313,288.75 | 56,674.00 |
 Astrazeneca Plc |
288,001.56 | 58,739.00 |
| SUBTOTAL | 4,166,795.71 | 656,265.61 |
Sign in to see all competitors of Aptevo Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Aptevo Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Aptevo Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Aptevo Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Affimed | Company report | 85% |
| Crescendo Biologics | Company report | 85% |
| Innate Pharma | Company report | 85% |
| Molecular Partners | Company report | 85% |
| U of Bern | Company report | 85% |
| Biotecnol | Company report | 85% |
| Gilead | Company report | 85% |
| MD Andersen CC | Company report | 85% |
| Shattuck Labs | Company report | 85% |
| ALX Oncology | Company report | 85% |
| Cullinan | Company report | 85% |
| Lava | Company report | 85% |
| Novartis | Company report | 85% |
| Xencor | Company report | 85% |
| Chiome Biosciences | Company report | 85% |
| ImmunoGen | Company report | 85% |
| Menarini Group | Company report | 85% |
| Syros Pharma | Company report | 85% |
| Bio-Path | Company report | 85% |
| Faron Pharma | Company report | 85% |
| Macrogenics | Company report | 85% |
| Sanofi | Company report | 85% |
| Bio-Path | Company report | 85% |
Company report basis, confidence, active dates and source counts for Aptevo Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Aptevo Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Aptevo Therapeutics Inc .
Aptevo Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Aptevo Therapeutics Inc | 1 | 360,694 | -736,250 |
| Eli Lilly And Company | 1,278,223 | 1,729,240 | 551,594 |
| Johnson and Johnson | 694,227 | 705,504 | 114,311 |
| Merck and Co Inc | 362,967 | 887,587 | 42,267 |
| Novartis Ag | 313,289 | 752,973 | 185,566 |
| Astrazeneca Plc | 288,002 | 706,847 | 123,141 |
| PEERS TOTAL | 4,166,795 | 998,531 | 154,641 |
Sign in to see all peers for Aptevo Therapeutics Inc .
Aptevo Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Aptevo Therapeutics Inc .
Aptevo Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Aptevo Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Aptevo Therapeutics Inc ranks #459 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 995, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,278,652 | 24.03 % |
| 2 | Johnson and Johnson | 691,817 | 13.00 % |
| 3 | Abbvie Inc | 521,524 | 9.80 % |
| 4 | Merck and Co Inc | 362,966 | 6.82 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 459 | Aptevo Therapeutics Inc | 1 | 0.00 % |
Market cap and industry share for the rest of Aptevo Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Aptevo Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 454 | Skinvisible Inc | 1 | - |
| 455 | Protagenic Therapeutics Inc new | 1 | - |
| 456 | Axim Biotechnologies Inc | 1 | - |
| 457 | Protokinetix Incorporated | 1 | - |
| 458 | Evofem Biosciences Inc | 1,234 | 12.3% |
| 459 | Aptevo Therapeutics Inc | 1 | -97.19 % |
| 460 | Pmgc Holdings Inc | 1,234 | 12.3% |
| 461 | The Greater Cannabis Company Inc | 1,234 | 12.3% |
| 462 | Artelo Biosciences Inc | 1,234 | 12.3% |
| 463 | Decoy Therapeutics Inc | 1,234 | 12.3% |
| 464 | Karyopharm Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Aptevo Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-12. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Aptevo Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.0x | 26.3x | -26.3x |
| EV / EBITDA | - | 15.1x | - |
| P/B | 0.4x | 4.2x | -3.8x |
| Return on Equity | -202.23 % | industry aggregate | -218.58 % |
| Return on Invested Capital | -88.02 % | -9.73 % (avg) | -78.29 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Aptevo Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 57.37 % | 40.56 % | - | - | - | - | - | - |
| Operating Margin | -223.98 % | -131.37 % | - | -174.10 % | - | - | - | - |
| Return on Invested Capital | -44.25 % | -68.85 % | -77.79 % | -51.45 % | -74.66 % | -74.27 % | -166.17 % | -106.54 % |
| P/E | - | - | - | - | 0.0x | - | - | 0.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Aptevo Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Aptevo Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Aptevo Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 995 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Aptevo Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Aptevo Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Aptevo Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Aptevo Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 218.6 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-497.0% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (48.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Aptevo Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Aptevo Therapeutics Inc | 4.43 | 3.36 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Aptevo Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Aptevo Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Aptevo Therapeutics Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +10.1 % | -2.3 % |
Sign in to see all peers for Aptevo Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Aptevo Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Aptevo Therapeutics Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Aptevo Therapeutics Inc .
Aptevo Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Aptevo Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Aptevo Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Aptevo Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Aptevo Therapeutics Inc | 0.00 | 0.06 |
| Eli Lilly And Company | 46.45 | 14.78 |
| Johnson and Johnson | 42.89 | 6.99 |
| Merck and Co Inc | 118.51 | 5.45 |
| Novartis Ag | 22.40 | 5.53 |
| Astrazeneca Plc | 28.19 | 4.90 |
| PEERS AVERAGE | 41.01 | 6.35 |
Sign in to see all peers for Aptevo Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.